Search

Your search keyword '"Piscaglia F."' showing total 1,361 results

Search Constraints

Start Over You searched for: Author "Piscaglia F." Remove constraint Author: "Piscaglia F."
1,361 results on '"Piscaglia F."'

Search Results

2. Boundary Conditions and SGS Models for LES of Wall-Bounded Separated Flows: An Application to Engine-Like Geometries

6. Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients

7. Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research

8. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

9. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

11. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma

14. 88P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)

16. Clinical impact of relative dose intensity of cabozantinib during the first 8 weeks and of subsequent dose reductions in patients with unresectable hepatocellular carcinoma

18. Predictors of extrahepatic progression in patients with hepatocellular carcinoma receiving transarterial chemoembolization

23. Preoperative predictors of recurrence beyond Milan criteria in hepatocellular carcinoma patients treated with frontline liver resection

24. Incidence and risk factors of esophagogastric varices bleeding in cirrhotic patients with advanced hepatocellular carcinoma treated with lenvatinib

26. Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di)

27. MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma

31. 67P Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

32. 65P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population

34. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications

35. Pattern of macrovascular invasion in hepatocellular carcinoma

36. Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI)

43. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib

45. Epidemiological, virological and clinical profile of HBsAg positive individuals in Italian hospital settings: interim results of the HBV/HDV PITER cohort

Catalog

Books, media, physical & digital resources